Alongside its work on a second-generation mRNA vaccine program with GSK (initially focused in opposition to COVID-19 and influenza with candidates in Phase 1 trials), CureVac will up its focus in oncology.“We are translating the essential insights and findings we have now made within the development of mRNA expertise to our oncology applications,” stated Franz-Werner Haas, CEO, as the corporate launched its Q1 2022 outcomes this month.myNEO partnershipAs introduced final week, the German mRNA firm will enter a analysis and choice settlement with Belgium-based immunotherapy firm myNEO, Under the settlement, each corporations purpose to establish particular antigens discovered on the floor of tumors for the development of novel mRNA immunotherapies: leveraging myNEO’s organic datasets and its built-in machine studying and bioinformatics platform.myNEO makes use of a broad vary of underlying genomic alterations to establish always rising, novel lessons of antigens of outlined tumor sorts. The immunogenicity of recognized antigens is predicted utilizing proprietary algorithms, machine and deep studying strategies and an in depth database containing information on tumor particular mutations. Incorporating new rating methodologies based mostly on tumor cell antigen processing and presentation permits for choice of antigens with the best confidence of success for potential medical testing, in accordance with the corporate.Three pillars in oncologyThe collaboration with myNEO, nonetheless, is only one of three pillars within the firm’s oncology efforts.“Partnering with myNEO represents step one within the focused growth of CureVac’s distinctive mRNA method for the development of novel cancer vaccines,” notes the corporate.“Taking benefit of latest expertise platform advances, CureVac is creating the oncology space based mostly on three strategic pillars. In addition to accessing novel lessons of tumor antigens, these pillars embrace the validation and optimization of CureVac’s mRNA expertise concerning robust induction of tumor-killing T cells. The firm additionally plans so as to add complementary platforms for antigen discovery and improved vaccine design with a focus on environment friendly T cell activation. CureVac intends to leverage The RNA Printer, its automated end-to-end answer for smaller-scale, speedy manufacturing of GMP-grade mRNA vaccines and therapeutics.”
https://www.biopharma-reporter.com/Article/2022/05/30/curevac-increases-focus-on-cancer-vaccine-development
Curevac increases focus on cancer vaccine development
